Clinical Trial Update: Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers [Phase 3]

View source ↗

Summary

This entry notes the termination and posting of results for an open-label extension study of Rosiglitazone XR as adjunctive therapy in mild-to-moderate Alzheime…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Rosiglitazone XR (rosiglitazone extended-release)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2017-11-13